{"disease":{"id":"neovascular-glaucoma","name":"Neovascular glaucoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Neovascular glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"eylea","indication_name":"Neovascular glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04381611","title":"INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"Dr. Kaweh Mansouri","has_results":false},{"nct_id":"NCT05130385","title":"High Resolution Optical Coherence Tomography","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT04519619","title":"Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)","phase":"","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07177807","title":"Clinical Characteristics of Neovascular Glaucoma","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT01908816","title":"An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04215575","title":"Baerveldt (BGI) Valve Versus Ahmed(AGV) Valve in Management of Difficult Glaucoma Cases","phase":"NA","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT05316142","title":"Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Iran University of Medical Sciences","has_results":false},{"nct_id":"NCT03187418","title":"Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":true},{"nct_id":"NCT04844619","title":"KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05156021","title":"A Study on the Treatment Strategy of NVG Secondary to PDR","phase":"NA","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07201415","title":"Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT03154892","title":"The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Second Affiliated Hospital of Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04970251","title":"Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT00727038","title":"Lucentis for New Onset Neovascular Glaucoma","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}